Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data

Vaccine

Volumn 34, Issue 49, 2016, Pages 6015-6026

  DeSilva, Malini ^a   Munoz, Flor M ^b   Mcmillan, Mark ^c,d   Kawai, Alison Tse ^e   Marshall, Helen ^d   Macartney, Kristine K ^f,g   Joshi, Jyoti ^h   Oneko, Martina ⁱ   Rose, Annette Elliott ^j   Dolk, Helen ^k   Trotta, Francesco ^l   Spiegel, Hans ^m   Tomczyk, Sylvie ⁿ   Shrestha, Anju ^o   Kochhar, Sonali ^p   Kharbanda, Elyse O ^a  

^a HEALTHPARTNERS INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e HARVARD MEDICAL SCHOOL   (United States)

^f National Centre for Immunisation Research Surveillance (NCIRS)   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h PUBLIC HEALTH FOUNDATION OF INDIA   (India)

ⁱ KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^j Reproductive Care Program of Nova Scotia   (Canada)

^k UNIVERSITY OF ULSTER   (United Kingdom)

^l Ufficio di Farmacovigilanza   (Italy)

^m HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

ⁿ Novartis Vaccines Cambridge   (United States)

^o SANOFI PASTEUR   (France)

^p Healthcare Management Consultants   (India)

more..

Author keywords

Adverse event; Birth defect; Case definition; Congenital abnormality; Congenital anomaly; Congenital disorders; Congenital malformations; Guidelines; Immunization

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; VACCINE; WART VIRUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ARTICLE; CHICKENPOX; CLASSIFICATION; CONGENITAL MALFORMATION; DIAGNOSTIC VALUE; DIPHTHERIA; DRUG SAFETY; HUMAN; IMMUNIZATION; INFLUENZA; INFORMATION PROCESSING; MEASLES; MENINGOCOCCEMIA; META ANALYSIS (TOPIC); MUMPS; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLIOMYELITIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RUBELLA; SYSTEMATIC REVIEW (TOPIC); TETANUS; YELLOW FEVER; CONGENITAL DISORDER; FEMALE; PREGNANCY COMPLICATION;

CONGENITAL ABNORMALITIES; DATA COLLECTION; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; GUIDELINES AS TOPIC; HUMANS; IMMUNIZATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VACCINES;

EID: 84999779384     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.047     Document Type: Article

References (70)

1. [1] Khoury, M.J., Epidemiology of birth defects. Epidemiol Rev 11 (1989), 244–248.
2. [2] Naghavi, M., Wang, H., Lozano, R., Davis, A., Liang, X., Zhou, M., et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
3. [3] Rasmussen, S.A., Olney, R.S., Holmes, L.B., Lin, A.E., Keppler-Noreuil, K.M., Moore, C.A., Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67 (2003), 193–201.
4. [4] Wellesley, D., Boyd, P., Dolk, H., Pattenden, S., An aetiological classification of birth defects for epidemiological research. J Med Genet 42 (2005), 54–57.
5. [5] Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60 (2011), 1128–1132.
6. [6] Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec 87 (2012), 461–476.
7. [7] Christian, L.M., Iams, J.D., Porter, K., Glaser, R., Inflammatory responses to trivalent influenza virus vaccine among pregnant women. Vaccine 29 (2011), 8982–8987.
8. [8] Christian, L.M., Porter, K., Karlsson, E., Schultz-Cherry, S., Iams, J.D., Serum proinflammatory cytokine responses to influenza virus vaccine among women during pregnancy versus non-pregnancy. Am J Reprod Immunol 70 (2013), 45–53.
9. [9] Chambers, C.D., Johnson, D., Xu, R., Luo, Y., Louik, C., Mitchell, A.A., et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine 31 (2013), 5026–5032.
10. [10] Deinard, A.S., Ogburn, P., A/NJ/8/76 influenza vaccination program: effects on maternal health and pregnancy outcome. Am J Obstet Gynecol 140 (1981), 240–245.
11. [11] Heikkinen, T., Young, J., van Beek, E., Franke, H., Verstraeten, T., Weil, J.G., et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol, 207, 2012 177 e1–8.
12. [12] Kallen, B., Olausson, P.O., Vaccination against H1N1 influenza with Pandemrix((R)) during pregnancy and delivery outcome: a Swedish register study. BJOG 119 (2012), 1583–1590.
13. [13] Launay, O., Krivine, A., Charlier, C., Truster, V., Tsatsaris, V., Lepercq, J., et al. Low rate of pandemic A/H1N1 2009 influenza infection and lack of severe complication of vaccination in pregnant women: a prospective cohort study. PLoS ONE, 7, 2012, e52303.
14. [14] Louik, C., Ahrens, K., Kerr, S., Pyo, J., Chambers, C., Jones, K.L., et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects. Vaccine 31 (2013), 5033–5040.
15. [15] Mackenzie, I.S., MacDonald, T.M., Shakir, S., Dryburgh, M., Mantay, B.J., McDonnell, P., et al. Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes. Br J Clin Pharmacol 73 (2012), 801–811.
16. [16] Oppermann, M., Fritzsche, J., Weber-Schoendorfer, C., Keller-Stanislawski, B., Allignol, A., Meister, R., et al. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 30 (2012), 4445–4452.
17. [17] Pasternak, B., Svanstrom, H., Molgaard-Nielsen, D., Krause, T.G., Emborg, H.D., Melbye, M., et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA 308 (2012), 165–174.
18. [18] Rubinstein, F., Micone, P., Bonotti, A., Wainer, V., Schwarcz, A., Augustovski, F., et al. Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ, 346, 2013, f393.
19. [19] Sheffield, J.S., Greer, L.G., Rogers, V.L., Roberts, S.W., Lytle, H., McIntire, D.D., et al. Effect of influenza vaccination in the first trimester of pregnancy. Obstet Gynecol 120 (2012), 532–537.
20. [20] Munoz, F.M., Englund, J.A., Cheesman, C.C., Maccato, M.L., Pinell, P.M., Nahm, M.H., et al. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 20 (2001), 826–837.
21. [21] McMillan, M., Porritt, K., Kralik, D., Costi, L., Marshall, H., Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine 33 (2015), 2108–2117.
22. [22] Demicheli, V., Jefferson, T., Al-Ansary Lubna, A., Ferroni, E., Rivetti, A., Di Pietrantonj, C., Vaccines for preventing influenza in healthy adults. Cochrane database of systematic reviews. 2014, John Wiley & Sons, Ltd.
23. [23] Fabiani, M., Bella, A., Rota, M.C., Clagnan, E., Gallo, T., D'Amato, M., et al. A/H1N1 pandemic influenza vaccination: a retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy. Vaccine 33 (2015), 2240–2247.
24. [24] Trotta, F., Da Cas, R., Spila Alegiani, S., Gramegna, M., Venegoni, M., Zocchetti, C., et al. Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study. BMJ, 348, 2014, g3361.
25. [25] Huang, W.T., Tang, F.W., Yang, S.E., Chih, Y.C., Chuang, J.H., Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan. Vaccine 32 (2014), 6463–6468.
26. [26] Pertussis vaccines: WHO position paper – September 2015. Wkly Epidemiol Rec 90 (2015), 433–458.
27. [27] Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women—Advisory Committee on Immunization Practices (ACIP) 2012. MMWR Morb Mortal Wkly Rep 62 (2013), 131–135.
28. [28] Munoz, F.M., Bond, N.H., Maccato, M., Pinell, P., Hammill, H.A., Swamy, G.K., et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 311 (2014), 1760–1769.
29. [29] Shakib, J.H., Korgenski, K., Sheng, X., Varner, M.W., Pavia, A.T., Byington, C.L., Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. J Pediatr, 163, 2013 1422–6 e1–4.
30. [30] Morgan, J.L., Baggari, S.R., McIntire, D.D., Sheffield, J.S., Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination. Obstet Gynecol 125 (2015), 1433–1438.
31. [31] Zheteyeva, Y.A., Moro, P.L., Tepper, N.K., Rasmussen, S.A., Barash, F.E., Revzina, N.V., et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol, 207, 2012 59 e1–7.
32. [32] Tetanus vaccine. Wkly Epidemiol Rec 81 (2006), 198–208.
33. [33] Heinonen, O., Slone, D., Shapiro, S., Birth defects and drugs in pregnancy. 1977, Publishing Sciences Group.
34. [34] Czeizel, A.E., Rockenbauer, M., Tetanus toxoid and congenital abnormalities. Int J Gynaecol Obstet 64 (1999), 253–258.
35. [35] Silveira, C.M., Caceres, V.M., Dutra, M.G., Lopes-Camelo, J., Castilla, E.E., Safety of tetanus toxoid in pregnant women: a hospital-based case-control study of congenital anomalies. Bull World Health Organ 73 (1995), 605–608.
36. [36] TORCH syndrome and TORCH screening. Lancet 335 (1990), 1559–1561.
37. [37] Keller-Stanislawski, B., Englund, J.A., Kang, G., Mangtani, P., Neuzil, K., Nohynek, H., et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine 32 (2014), 7057–7064.
38. [38] Bar-Oz, B., Levichek, Z., Moretti, M.E., Mah, C., Andreou, S., Koren, G., Pregnancy outcome following rubella vaccination: a prospective controlled study. Am J Med Genet Part A 130A (2004), 52–54.
39. [39] da Silva e Sa, G.R., Camacho, L.A., Stavola, M.S., Lemos, X.R., Basilio de Oliveira, C.A., Siqueira, M.M., Pregnancy outcomes following rubella vaccination: a prospective study in the state of Rio de Janeiro Brazil, 2001–2002. J Infect Dis 204:Suppl. 2 (2011), S722–S728.
40. [40] Badilla, X., Morice, A., Avila-Aguero, M.L., Saenz, E., Cerda, I., Reef, S., et al. Fetal risk associated with rubella vaccination during pregnancy. Pediatr Infect Dis J 26 (2007), 830–835.
41. [41] Minussi, L., Mohrdieck, R., Bercini, M., Ranieri, T., Sanseverino, M.T., Momino, W., et al. Prospective evaluation of pregnant women vaccinated against rubella in southern Brazil. Reprod Toxicol 25 (2008), 120–123.
42. [42] Pardon, F., Vilarino, M., Barbero, P., Garcia, G., Outon, E., Gil, C., et al. Rubella vaccination of unknowingly pregnant women during 2006 mass campaign in Argentina. J Infect Dis 204:Suppl. 2 (2011), S745–S747.
43. [43] Soares, R.C., Siqueira, M.M., Toscano, C.M., Maia Mde, L., Flannery, B., Sato, H.K., et al. Follow-up study of unknowingly pregnant women vaccinated against rubella in Brazil, 2001–2002. J Infect Dis 204:Suppl. 2 (2011), S729–S736.
44. [44] Hamkar, R., Jalilvand, S., Abdolbaghi, M.H., Esteghamati, A.R., Hagh-Goo, A., Jelyani, K.N., et al. Inadvertent rubella vaccination of pregnant women: evaluation of possible transplacental infection with rubella vaccine. Vaccine 24 (2006), 3558–3563.
45. [45] Castillo-Solorzano, C., Reef, S.E., Morice, A., Vascones, N., Chevez, A.E., Castalia-Soares, R., et al. Rubella vaccination of unknowingly pregnant women during mass campaigns for rubella and congenital rubella syndrome elimination, the Americas 2001–2008. J Infect Dis 204:Suppl. 2 (2011), S713–S717.
46. [46] Sukumaran, L., McNeil, M.M., Moro, P.L., Lewis, P.W., Winiecki, S.K., Shimabukuro, T.T., Adverse events following measles, mumps, and rubella vaccine in adults reported to the vaccine adverse event reporting system (VAERS), 2003–2013. Clin Infect Dis 60 (2015), e58–e65.
47. [47] Burton, A.E., Robinson, E.T., Harper, W.F., Bell, E.J., Boyd, J.F., Fetal damage after accidental polio vaccination of an immune mother. J R Coll Gen Pract 34 (1984), 390–394.
48. [48] Harjulehto-Mervaala, T., Aro, T., Hiilesmaa, V.K., Hovi, T., Saxen, H., Saxen, L., Oral polio vaccination during pregnancy: lack of impact on fetal development and perinatal outcome. Clin Infect Dis 18 (1994), 414–420.
49. [49] Suzano, C.E., Amaral, E., Sato, H.K., Papaiordanou, P.M., Campinas Group on Yellow Fever Immunization during Pregnancy. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24 (2006), 1421–1426.
50. [50] Cavalcanti, D.P., Salomao, M.A., Lopez-Camelo, J., Pessoto, M.A., Campinas Group of Yellow Fever Immunization during Pregnancy. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 12 (2007), 833–837.
51. [51] Wilson, E., Goss, M.A., Marin, M., Shields, K.E., Seward, J.F., Rasmussen, S.A., et al. Varicella vaccine exposure during pregnancy: data from 10 years of the pregnancy registry. J Infect Dis 197:Suppl. 2 (2008), S178–S184.
52. [52] Angelo, M.G., David, M.P., Zima, J., Baril, L., Dubin, G., Arellano, F., et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 23 (2014), 466–479.
53. [53] Garland, S.M., Ault, K.A., Gall, S.A., Paavonen, J., Sings, H.L., Ciprero, K.L., et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 114 (2009), 1179–1188.
54. [54] Dana, A., Buchanan, K.M., Goss, M.A., Seminack, M.M., Shields, K.E., Korn, S., et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 114 (2009), 1170–1178.
55. [55] Goss, M.A., Lievano, F., Buchanan, K.M., Seminack, M.M., Cunningham, M.L., Dana, A., Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 33 (2015), 3422–3428.
56. [56] Angelo, M.G., Zima, J., Tavares Da Silva, F., Baril, L., Arellano, F., Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 23 (2014), 456–465.
57. [57] Moro, P.L., Zheteyeva, Y., Lewis, P., Shi, J., Yue, X., Museru, O.I., et al. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006–2013. Vaccine 33 (2015), 519–522.
58. [58] Nakalembe, M., Mirembe, F.M., Banura, C., Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy. Infect Agents Cancer, 10, 2015, 17.
59. [59] Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372 (2015), 711–723.
60. [60] Makris, M.C., Polyzos, K.A., Mavros, M.N., Athanasiou, S., Rafailidis, P.I., Falagas, M.E., Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review. Drug Saf 35 (2012), 1–14.
61. [61] Zheteyeva, Y., Moro, P.L., Yue, X., Broder, K., Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol, 208, 2013 478 e1–6.
62. [62] Ouandaogo, C.R., Yameogo, T.M., Diomande, F.V., Sawadogo, C., Ouedraogo, B., Ouedraogo-Traore, R., et al. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine 30:Suppl. 2 (2012), B46–B51.
63. [63] Update on overall prevalence of major birth defects—Atlanta, Georgia, 1978–2005. MMWR Morb Mortal Wkly Rep 57 (2008), 1–5.
64. [64] Population-based Birth Defects Surveillance data from selected states, 2002–2006. Birth Defects Res A Clin Mol Teratol 85 (2009), 939–1055.
65. [65] Kohl, K.S., Gidudu, J., Bonhoeffer, J., Braun, M.M., Buettcher, M., Chen, R.T., et al. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine 25 (2007), 5671–5674.
66. [66] Obican, S., Scialli, A.R., Teratogenic exposures. Am J Med Genet Part C: Semin Med Genet 157C (2011), 150–169.
67. [67] Shiota, K., Variability in human embryonic development and its implications for the susceptibility to environmental teratogenesis. Birth Defects Res A Clin Mol Teratol 85 (2009), 661–666.
68. [68] Rasmussen, S.A., Human teratogens update 2011: can we ensure safety during pregnancy?. Birth Defects Res A Clin Mol Teratol 94 (2012), 123–128.
69. [69] International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
70. [70] Council for International Organizations of Medical Sciences.